Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › KS › Overland Park › NPI 1285014282
Lab

Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings was paid $26.12M by Medicaid between Jan 2018 and Dec 2024, across 253 billing codes. Its largest line is 87591, Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe — 5.6% of everything it billed.

33Billing provider infoLABORATORY CORPORATION OF AMERICA HOLDINGS
OVERLAND PARK, KS 66210
33aNPI1285014282assigned 06/04/2015
33bProvider typeClinical Medical Laboratory
28Total paid$26.12M
24GClaims2,585,481
24DCodes billed253
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in Kansas

Rank by total paid#2 of 47
Median peer was paid$64K
This provider vs. median409×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official WILLIAMS, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$500K$1.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201861,774$499K
2019136,204$1.20M
2020282,189$2.41M
2021424,115$3.83M
2022586,661$6.36M
2023628,121$7.15M
2024incomplete466,417$4.66M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 5.6% 62,683 60,274 $1.46M
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 5.5% 61,043 58,632 $1.44M
84443 Thyroid stimulating hormone (TSH) 5.5% 142,686 137,002 $1.43M
80053 Comprehensive metabolic panel 5.2% 212,167 202,517 $1.37M
80061 Lipid panel 5.0% 168,938 162,325 $1.31M
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 4.5% 63,498 61,156 $1.16M
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel 4.2% 2,933 2,855 $1.09M
85025 Blood count; complete (CBC), automated, and automated differential WBC count 3.6% 205,518 193,878 $933K
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants 3.5% 2,750 2,647 $926K
80050 General health panel 3.5% 33,775 32,376 $922K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 3.3% 54,836 52,418 $868K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 3.0% 35,892 34,911 $780K
241 more codes
80081 2.9% 14,521 $767K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 2.9% 20,716 $760K
83036 Hemoglobin; glycosylated (A1C) 2.7% 123,039 $694K
86480 1.9% 13,209 $484K
86803 1.8% 55,147 $468K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 1.7% 7,628 $456K
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer 1.6% 26,155 $413K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types 1.5% 18,274 $390K
84439 1.3% 65,127 $332K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 1.1% 6,825 $275K
80074 1.0% 9,959 $273K
82607 1.0% 30,714 $266K
80055 <1% 9,206 $244K
82728 <1% 27,657 $213K
84403 <1% 11,479 $173K
82746 <1% 19,771 $170K
87660 <1% 12,577 $166K
87086 Culture, bacterial; quantitative colony count, urine <1% 32,172 $151K
80048 Basic metabolic panel (calcium, ionized) <1% 33,772 $149K
87480 <1% 12,574 $149K
87536 <1% 2,857 $146K
36415 Collection of venous blood by venipuncture <1% 112,039 $143K
87340 <1% 21,666 $134K
87510 <1% 12,413 $132K
83550 <1% 24,937 $126K
85027 <1% 31,143 $123K
84153 <1% 11,984 $121K
84702 <1% 14,669 $121K
86780 <1% 14,267 $110K
82570 <1% 36,140 $105K
83540 <1% 28,401 $104K
84146 <1% 9,222 $102K
86592 <1% 36,432 $98K
83001 <1% 8,993 $97K
87522 Neg quan hep c or qual rna <1% 3,784 $96K
82043 <1% 30,417 $96K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 1,299 $95K
86787 <1% 12,697 $95K
84481 <1% 10,288 $94K
82670 <1% 5,900 $94K
83970 <1% 4,622 $90K
83655 <1% 11,033 $87K
84402 <1% 5,675 $83K
82950 <1% 24,821 $77K
86360 <1% 2,684 $72K
83880 <1% 3,628 $68K
84144 <1% 5,106 $65K
83002 <1% 6,337 $65K
86235 <1% 1,007 $63K
86038 <1% 8,139 $60K
86850 <1% 10,121 $59K
86706 <1% 9,327 $59K
86762 <1% 7,416 $57K
86140 <1% 19,141 $56K
86003 <1% 959 $54K
82274 <1% 5,994 $54K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 2,107 $53K
86696 <1% 4,358 $52K
87902 <1% 354 $51K
84436 <1% 12,632 $50K
81329 <1% 1,802 $47K
81001 <1% 26,506 $47K
88141 <1% 3,341 $46K
83735 <1% 12,610 $46K
86376 <1% 5,500 $45K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 1,328 $43K
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms <1% 1,094 $43K
82951 <1% 4,951 $42K
80076 <1% 8,539 $40K
86704 <1% 5,764 $40K
87088 <1% 8,885 $40K
87186 <1% 7,750 $39K
82784 <1% 4,191 $33K
86695 <1% 4,117 $32K
83690 <1% 7,704 $31K
83020 <1% 4,239 $31K
80164 <1% 4,348 $29K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 1,267 $27K
84479 <1% 7,004 $26K
82105 <1% 2,882 $26K
81243 <1% 1,566 $26K
85652 <1% 16,009 $25K
84480 <1% 3,220 $25K
82248 <1% 9,100 $25K
83525 <1% 3,807 $25K
87150 <1% 1,304 $24K
86665 <1% 1,354 $24K
85060 <1% 2,012 $23K
87625 <1% 880 $22K
87077 <1% 4,909 $22K
82627 <1% 1,832 $22K
85610 <1% 9,933 $22K
84550 <1% 8,426 $22K
86431 <1% 6,213 $22K
82947 <1% 9,610 $21K
86800 <1% 2,191 $20K
83021 <1% 1,714 $20K
82150 <1% 5,197 $19K
84156 <1% 9,749 $19K
82565 <1% 7,646 $19K
84450 <1% 6,963 $18K
86364 <1% 1,843 $17K
88142 <1% 1,439 $17K
80069 <1% 3,768 $16K
82247 <1% 6,176 $16K
83516 <1% 1,101 $16K
83615 <1% 4,438 $16K
86870 <1% 784 $15K
84460 <1% 5,873 $15K
86901 <1% 7,391 $15K
86708 <1% 2,237 $15K
80178 <1% 3,891 $14K
86900 <1% 7,333 $14K
86200 <1% 1,722 $13K
84520 <1% 6,180 $13K
82977 <1% 3,274 $12K
84681 <1% 1,073 $12K
85018 <1% 8,091 $12K
82533 <1% 1,310 $12K
82672 <1% 921 $12K
82952 <1% 4,534 $12K
82652 <1% 914 $11K
80305 <1% 2,149 $11K
82310 <1% 4,572 $11K
82040 <1% 4,446 $11K
84075 <1% 4,272 $10K
82550 <1% 3,057 $10K
86317 <1% 1,128 $10K
85014 <1% 6,666 $10K
87081 <1% 2,515 $10K
85045 <1% 4,234 $10K
84466 <1% 1,322 $10K
85730 <1% 2,942 $9K
82785 <1% 1,004 $9K
84155 <1% 5,066 $9K
86361 <1% 642 $9K
86664 <1% 1,051 $9K
86225 <1% 1,091 $9K
84295 <1% 3,780 $9K
86160 <1% 1,224 $8K
84703 <1% 1,893 $8K
83498 <1% 567 $8K
84100 <1% 3,551 $8K
86258 <1% 704 $8K
82435 <1% 3,631 $8K
87563 <1% 393 $8K
85660 <1% 2,065 $7K
86593 <1% 2,565 $7K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 66 $7K
83721 <1% 1,507 $7K
84165 <1% 1,289 $7K
86705 <1% 990 $7K
84154 <1% 667 $6K
80051 <1% 1,686 $6K
84238 <1% 323 $6K
83013 <1% 149 $6K
82330 <1% 792 $6K
84132 <1% 2,451 $6K
86735 <1% 740 $6K
82465 <1% 2,092 $6K
86765 <1% 714 $5K
85041 <1% 2,667 $5K
82103 <1% 702 $5K
85048 <1% 2,770 $5K
82374 <1% 2,014 $4K
86769 <1% 109 $4K
86381 <1% 324 $4K
86618 <1% 378 $4K
82140 <1% 475 $4K
85379 <1% 770 $3K
86141 <1% 473 $3K
88307 <1% 62 $3K
86709 <1% 569 $3K
87529 <1% 121 $3K
82390 <1% 485 $3K
81003 <1% 2,310 $3K
86015 <1% 430 $3K
84425 <1% 201 $3K
86304 <1% 243 $3K
87350 <1% 328 $2K
84163 <1% 274 $2K
88342 <1% 100 $2K
86060 <1% 489 $2K
86645 <1% 204 $2K
82024 <1% 89 $2K
G0307 Complete (cbc), automated (hgb, hct, rbc, wbc; without platelet count) <1% 514 $2K
86644 <1% 218 $2K
81015 <1% 916 $2K
83921 <1% 145 $1K
87535 <1% 65 $1K
86147 <1% 31 $1K
82575 <1% 161 $967.77
87517 <1% 41 $903.75
82378 <1% 90 $863.88
83521 <1% 43 $768.59
86308 <1% 243 $749.47
84270 <1% 56 $707.15
84630 <1% 102 $695.51
84206 <1% 57 $649.44
86677 <1% 146 $649.42
G0145 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision <1% 85 $646.81
86707 <1% 87 $607.51
84134 <1% 70 $573.72
85384 <1% 102 $551.15
86777 <1% 72 $540.78
88304 <1% 83 $508.20
84445 <1% 14 $498.51
81025 <1% 104 $471.18
86702 <1% 61 $453.75
88112 <1% 12 $450.50
87209 <1% 43 $431.40
86300 <1% 25 $427.53
82397 <1% 60 $423.67
82104 <1% 39 $337.72
83520 <1% 39 $334.48
86701 <1% 61 $300.30
G0103 Prostate cancer screening; prostate specific antigen test (psa) <1% 341 $290.49
87070 <1% 57 $285.38
86682 <1% 29 $270.85
88313 <1% 13 $269.59
82239 <1% 30 $248.11
84410 <1% 12 $240.15
84482 <1% 29 $217.04
87177 <1% 43 $213.60
83010 <1% 27 $192.20
83090 <1% 29 $179.15
87210 <1% 44 $159.27
82677 <1% 13 $137.69
84478 <1% 39 $121.33
86336 <1% 13 $117.17
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) <1% 41 $114.78
83718 <1% 23 $114.71
86334 <1% 14 $104.41
86663 <1% 12 $91.19
80175 <1% 12 $75.55
83883 <1% 13 $68.64
80197 <1% 15 $65.44
85007 <1% 31 $63.17
36416 <1% 188 $40.55
G0475 Hiv antigen/antibody, combination assay, screening 0% 12 $0.00
S3600 Stat laboratory request (situations other than s3601) 0% 33 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialWILLIAMS, KIMBERLY (VICE PRESIDENT)
Same official

Other billing entities under WILLIAMS, KIMBERLY

Full network →
ProviderLocationPaid
Laboratory Corporation of America HoldingsBurlington, NC$1.44B
Laboratory Corporation of America HoldingsRaritan, NJ$717.47M
Laboratory Corporation of America HoldingsDublin, OH$617.02M
Laboratory Corporation of America HoldingsBirmingham, AL$289.12M
Laboratory Corporation of AmericaPhoenix, AZ$265.90M
Laboratory Corporation of America HoldingsBurlington, NC$264.26M
Laboratory Corporation of America HoldingsCharleston, WV$220.04M
Laboratory Corporation of AmericaSeattle, WA$186.69M
Laboratory Corporation of AmericaTampa, FL$171.13M
Laboratory Corporation of AmericaSan Diego, CA$147.14M
Laboratory Corporation of AmericaHouston, TX$103.81M
Laboratory Corporation of AmericaEnglewood, CO$77.80M
Laboratory Corporation of AmericaDallas, TX$77.42M
Laboratory Corporation of AmericaBurlington, NC$59.75M
Medtox Laboratories, INCSaint Paul, MN$47.72M
Laboratory Corporation of America HoldingsBurlington, NC$15.65M
Laboratory Corporation of AmericaSan Antonio, TX$11.67M
Tri-Cities Laboratory, LLCKennewick, WA$8.69M
Laboratory Corporation of America HoldingsMonroe, LA$3.39M
Laboratory Corporation of AmericaItasca, IL$3.37M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.